Alexion: Positive Phase 3 Data for Hemoglobinuria Med at ASH

– First Conference Presentation of Results for ALXN1210 in Patients on Soliris® (Eculizumab) at ASH –

– Publications in Blood of Results for ALXN1210 in Complement Inhibitor-Naïve Patients and Patients on Soliris® –

– Presentation at ASH of New Results from Sensitivity Analyses in Inhibitor-Naïve Patients, and Analyses of C5 Inhibition and Breakthrough Hemolysis in Inhibitor-Naïve Patients and Patients on Soliris® –

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the presentation of comprehensive positive Phase 3 data for ALXN1210, the company’s investigational long-acting C5 complement inhibitor, at the American Society of Hematology (ASH) Annual Meeting, taking place December 1-4, 2018. The presentations included both previously announced and new data from the two large Phase 3 studies in patients with paroxysmal nocturnal hemoglobinuria (PNH) who had either never been treated with a complement inhibitor before or who had been stable on Soliris® treatment. The conference presentations coincided with publications in Blood of the positive results on all primary and key secondary endpoints from these two studies.

“We are excited by the increasing body of data from our two active comparator-controlled Phase 3 studies, the largest PNH Phase 3 program ever conducted, on clinically meaningful endpoints in this devastating and potentially life-threatening disease. We are particularly pleased by the positive data in patients converting to ALXN1210 from Soliris®,” said John Orloff, M.D., Executive Vice President and Head of Research & Development at Alexion. “Our ambition is to make ALXN1210 the new standard of care for patients with PNH.”

https://www.marketscreener.com/ALEXION-PHARMACEUTICALS-8334/news/Alexion-Pharmaceuticals-Comprehensive-Positive-Phase-3-Data-for-Alexion-rsquo-s-ALXN1210-in-Patien-27699502/